Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial

作者：Shun Lü, Lin Wu, Hong Jian, Ying Cheng, Qiming Wang, Jian Fang, Ziping Wang, Yanping Hu, Liang Han, Meili Sun, Liyun Miao, Cuimin Ding, Jiuwei Cui, Ke Wang, Baolan Li, Xingya Li, Feng Ye, Anwen Liu, Yueyin Pan, Shundong Cang, Hui Zhou, Xing Sun, Yuping Shen, Shuyan Wang, Wen Zhang, Yue He · 发表于：The Lancet Respiratory Medicine · 年份：2023 · DOI：10.1016/s2213-2600(23)00135-2 · 被引用次数：212 · 研究领域：Cancer Immunotherapy and Biomarkers、Lung Cancer Treatments and Mutations、Biosimilars and Bioanalytical Methods